<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384397</url>
  </required_header>
  <id_info>
    <org_study_id>MTA44</org_study_id>
    <nct_id>NCT00384397</nct_id>
  </id_info>
  <brief_title>A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers</brief_title>
  <official_title>An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, modified single-blind, randomized, parallel-group, multicenter,
      comparative trial in the United States designed to evaluate the immunogenicity and safety of
      two doses of Menactra vaccine administered alone, and concomitantly with other routine
      pediatric vaccines typically administered between 12 and 15 months of age.

      Primary Objective:

      To evaluate the antibody responses to meningococcal serogroups A, C, Y, and W-135.

      Secondary Objectives:

      Immunogenicity

        -  To evaluate the antibody responses to meningococcal serogroups A, C, Y, and W-135, when
           Menactra vaccine is administered alone or concomitantly with Hib and MMRV vaccines.

        -  To evaluate the antibody responses to meningococcal serogroups A, C, Y, and W-135, when
           Menactra vaccine is administered alone or concomitantly with PCV vaccine.

      Safety

      - To describe the safety profile within 7 and 30 days of each vaccination, and serious
      adverse events (SAEs) throughout the course of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)</measure>
    <time_frame>30 days post-visit 2 Menactra®</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least One Solicited Injection Site or Systemic Reaction Post-vaccination</measure>
    <time_frame>0-7 days post-vaccination</time_frame>
    <description>Injection site reactions: tenderness, erythema, and swelling at the Menactra site (Visits 1 and 2) and the measles-mumps-rubella, varicella (MMRV) and pneumococcal conjugate vaccine (PCV) sites (only Visit 2); Systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, and irritability following each vaccination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Antibody Titers ≥ 4 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)</measure>
    <time_frame>30 days post-Visit 2 Menactra®</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Meningococcal Serum Bactericidal Assay Using Human Complement Antibody Geometric Mean Titers Following Visit 2 Vaccination(s) at 12 Months.</measure>
    <time_frame>30 days post-Visit 2 Menactra®</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1128</enrollment>
  <condition>Meningococcal Meningitis</condition>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>Group 1: Menactra® Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Menactra® + MMRV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Menactra® + PCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1: Menactra® Vaccine</arm_group_label>
    <other_name>Menactra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Toxoid Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2: Menactra® + MMRV</arm_group_label>
    <other_name>Menactra®</other_name>
    <other_name>ProQuad®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Diphtheria Toxoid Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 3: Menactra® + PCV</arm_group_label>
    <other_name>Menactra®</other_name>
    <other_name>Prevnar®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, as determined by medical history and physical examination.

          -  Aged 9 months (249 to 291 days) at the time of enrollment.

          -  The parent or legal guardian has signed and dated the Institutional Review
             Board-approved informed consent form

        Exclusion Criteria:

          -  Serious acute or chronic disease (e.g., cardiac, renal, metabolic, rheumatologic,
             psychiatric, hematologic, or autoimmune disorders, diabetes, atopic conditions,
             congenital defects, convulsions, encephalopathy, blood dyscrasias, leukemia, lymphomas
             of any type, or other malignant neoplasms affecting the bone marrow or lymphatic
             system, acute untreated tuberculosis) that could interfere with trial conduct or
             completion.

          -  Known or suspected impairment of immunologic function.

          -  Acute medical illness within the last 72 hours, or temperature ≥ 100.4 ºF (≥ 38.0 ºC)
             at the time of enrollment.

          -  History of documented invasive meningococcal disease or previous meningococcal
             vaccination.

          -  Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C seropositivity
             as reported by the parent or legal guardian

          -  Received either immune globulin or other blood products within the last 3 months, or
             received injected or oral corticosteroids, or other immunomodulator therapy within 6
             weeks of the study vaccines. Individuals on a tapering dose schedule of oral steroids
             lasting &lt; 7 days and individuals (e.g., asthmatics) on a short schedule of oral
             steroids lasting 3 to 4 days may be included in the trial as long as they have not
             received more than one course within the last two weeks prior to enrollment. Topical
             steroids are not included in this exclusion criterion.

          -  Anticipated to receive oral or injected antibiotic therapy within the 72 hours prior
             to the study blood draw. Topical antibiotics or antibiotic drops are not included in
             this exclusion criterion.

          -  Suspected or known hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the study vaccines or a vaccine containing the same
             substances. For ProQuad vaccine recipients, this includes a hypersensitivity to
             gelatin or a history of anaphylactic reactions to neomycin.

          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular (IM)
             vaccination.

          -  Parent or legal guardian unable or unwilling to comply with the study procedures.

          -  Participation in another interventional clinical trial in the 30 days preceding
             enrollment, or participation in another clinical trial involving the investigation of
             a drug, vaccine, medical procedure, or medical device during the subject's trial
             period.

          -  Diagnosed with any condition which, in the opinion of the investigator, would pose a
             health risk to the subject or interfere with the evaluation of the vaccine.

          -  Received any vaccine in the 30-day period prior to receipt of study vaccine, or
             scheduled to receive any vaccination other than influenza vaccination and
             hyposensitization therapy in the 30-day period after receipt of any study vaccine.
             Hyposensitization therapy and influenza vaccination may be received up to two weeks
             before or two weeks after receiving the study vaccines. Subjects should not have
             received their 4th dose of Pneumococcal Conjugate (PCV) or Hib vaccine or their first
             dose of Measles-Mumps-Rubella-Varicella (MMRV) vaccine before enrollment.

          -  Personal or family history of Guillain-Barré Syndrome (GBS).

          -  History of seizures, including febrile seizures, or any other neurologic disorder.

          -  Known hypersensitivity to dry natural rubber latex (pertinent to the Menactra® vaccine
             needle shield)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>249 Days</minimum_age>
    <maximum_age>305 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cocoa Beach</city>
        <state>Florida</state>
        <zip>32931</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viera</city>
        <state>Florida</state>
        <zip>32955</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laurinburg</city>
        <state>North Carolina</state>
        <zip>28352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <results_first_submitted>May 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2011</results_first_posted>
  <disposition_first_submitted>March 31, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2010</disposition_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menactra vaccine</keyword>
  <keyword>Meningococcal meningitis</keyword>
  <keyword>Measles</keyword>
  <keyword>Mumps</keyword>
  <keyword>Rubella</keyword>
  <keyword>Varicella virus</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 20 September 2006 to 29 September 2007 at 71 US clinical centers.</recruitment_details>
      <pre_assignment_details>A total of 1118 participants were enrolled, vaccinated, and included in data analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Menactra® Vaccine</title>
          <description>Participants received one dose of Menactra® alone at age 9 months and a second dose of Menactra® at age 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Menactra® + MMRV</title>
          <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine at age 12 months.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Menactra® + PCV</title>
          <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with pneumococcal conjugate vaccine (PCV) at age 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="293"/>
                <participants group_id="P3" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="247"/>
                <participants group_id="P3" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Menactra® Vaccine</title>
          <description>Participants received one dose of Menactra® alone at age 9 months and a second dose of Menactra® at age 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Menactra® + MMRV</title>
          <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine at age 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Menactra® + PCV</title>
          <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with pneumococcal conjugate vaccine (PCV) at age 12 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="407"/>
            <count group_id="B2" value="293"/>
            <count group_id="B3" value="418"/>
            <count group_id="B4" value="1118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="407"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="418"/>
                    <measurement group_id="B4" value="1118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278.7" spread="10.55"/>
                    <measurement group_id="B2" value="279.8" spread="10.93"/>
                    <measurement group_id="B3" value="279.5" spread="11.11"/>
                    <measurement group_id="B4" value="279.3" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="217"/>
                    <measurement group_id="B4" value="562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="407"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="418"/>
                    <measurement group_id="B4" value="1118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)</title>
        <time_frame>30 days post-visit 2 Menactra®</time_frame>
        <population>Antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® Vaccine</title>
            <description>Participants received one dose of Menactra® alone at age 9 months and a second dose of Menactra® at age 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® + MMRV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine at age 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® + PCV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with pneumococcal conjugate vaccine (PCV) at age 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)</title>
          <population>Antibody titers were assessed in the per-protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Antibody Titers ≥ 4 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)</title>
        <time_frame>30 days post-Visit 2 Menactra®</time_frame>
        <population>Antibody titers were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® Vaccine</title>
            <description>Participants received one dose of Menactra® alone at age 9 months and a second dose of Menactra® at age 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® + MMRV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine at age 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® + PCV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with pneumococcal conjugate vaccine (PCV) at age 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Titers ≥ 4 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC)</title>
          <population>Antibody titers were assessed in the per-protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Meningococcal Serum Bactericidal Assay Using Human Complement Antibody Geometric Mean Titers Following Visit 2 Vaccination(s) at 12 Months.</title>
        <time_frame>30 days post-Visit 2 Menactra®</time_frame>
        <population>Geometric mean titers and their 95% Confidence Intervals, measured by SBA-HC, were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® Vaccine</title>
            <description>Participants received one dose of Menactra® alone at age 9 months and a second dose of Menactra® at age 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® + MMRV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine at age 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® + PCV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with pneumococcal conjugate vaccine (PCV) at age 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Meningococcal Serum Bactericidal Assay Using Human Complement Antibody Geometric Mean Titers Following Visit 2 Vaccination(s) at 12 Months.</title>
          <population>Geometric mean titers and their 95% Confidence Intervals, measured by SBA-HC, were assessed in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="180"/>
                <count group_id="O3" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningococcal Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="46.8" upper_limit="64.5"/>
                    <measurement group_id="O2" value="52" lower_limit="41.8" upper_limit="64.7"/>
                    <measurement group_id="O3" value="41" lower_limit="34.6" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.8" lower_limit="123.5" upper_limit="162.9"/>
                    <measurement group_id="O2" value="161.9" lower_limit="136.3" upper_limit="192.3"/>
                    <measurement group_id="O3" value="109.5" lower_limit="94.1" upper_limit="127.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="45.4" upper_limit="60.6"/>
                    <measurement group_id="O2" value="60.2" lower_limit="50.4" upper_limit="71.7"/>
                    <measurement group_id="O3" value="39.9" lower_limit="34.4" upper_limit="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningococcal Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="20.8" upper_limit="28.3"/>
                    <measurement group_id="O2" value="27.9" lower_limit="22.7" upper_limit="34.3"/>
                    <measurement group_id="O3" value="17.9" lower_limit="15.2" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least One Solicited Injection Site or Systemic Reaction Post-vaccination</title>
        <description>Injection site reactions: tenderness, erythema, and swelling at the Menactra site (Visits 1 and 2) and the measles-mumps-rubella, varicella (MMRV) and pneumococcal conjugate vaccine (PCV) sites (only Visit 2); Systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, and irritability following each vaccination.</description>
        <time_frame>0-7 days post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Menactra® Vaccine</title>
            <description>Participants received one dose of Menactra® alone at age 9 months and a second dose of Menactra® at age 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Menactra® + MMRV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine at age 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Menactra® + PCV</title>
            <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with pneumococcal conjugate vaccine (PCV) at age 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Solicited Injection Site or Systemic Reaction Post-vaccination</title>
          <description>Injection site reactions: tenderness, erythema, and swelling at the Menactra site (Visits 1 and 2) and the measles-mumps-rubella, varicella (MMRV) and pneumococcal conjugate vaccine (PCV) sites (only Visit 2); Systemic reactions: Fever (temperature), vomiting, crying abnormal, drowsiness, appetite lost, and irritability following each vaccination.</description>
          <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Reaction Post-Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Cries when limb is moved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Injection Site Reaction Post-Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness - Menactra Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Cries when limb is moved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - Menactra Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in) - Menactra Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - Menactra Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in) - Menactra Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness - MMRV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr 3 Tenderness (Cries when limb moved) MMRV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - MMRV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in) - MMRV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - MMRV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in) - MMRV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness - PCV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr 3 Tenderness (Cries when limb moved) PCV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema - PCV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 2.0 in) - PCV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling - PCV Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 2.0 in)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction Post-Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever (Any Route)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Any Route &gt; 103.1 ºF or &gt; 39.5 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (≥ 6 episodes per 24 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal (&gt; 3 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (Sleeps most of time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Appetite Lost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost (Refuses ≥ 3 feeds/meals)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (Inconsolable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction Post-Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever (Any Route)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Any Route &gt; 103.1 ºF or &gt; 39.5 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (≥ 6 episodes per 24 hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal (&gt; 3 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (Sleeps most of time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Appetite Lost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost (Refuses ≥ 3 feeds/meals)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (Inconsolable)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data for each participants were collected from the day of enrollment to the end of study, 9 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Menactra® Vaccine</title>
          <description>Participants received one dose of Menactra® alone at age 9 months and a second dose of Menactra® at age 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Menactra® + MMRV</title>
          <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine at age 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Menactra® + PCV</title>
          <description>Participants received one dose of Menactra® at age 9 months and a second dose of Menactra® concomitantly with pneumococcal conjugate vaccine (PCV) at age 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Barrett's esophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Condyloma acuminatum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus insulin-dependent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="407"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="293"/>
                <counts group_id="E3" subjects_affected="222" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="407"/>
                <counts group_id="E2" events="38" subjects_affected="29" subjects_at_risk="293"/>
                <counts group_id="E3" events="48" subjects_affected="40" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="75" subjects_affected="56" subjects_at_risk="407"/>
                <counts group_id="E2" events="54" subjects_affected="34" subjects_at_risk="293"/>
                <counts group_id="E3" events="64" subjects_affected="43" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="407"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="293"/>
                <counts group_id="E3" events="40" subjects_affected="37" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="407"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="293"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="81" subjects_affected="69" subjects_at_risk="407"/>
                <counts group_id="E2" events="55" subjects_affected="48" subjects_at_risk="293"/>
                <counts group_id="E3" events="96" subjects_affected="85" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="53" subjects_affected="47" subjects_at_risk="407"/>
                <counts group_id="E2" events="37" subjects_affected="33" subjects_at_risk="293"/>
                <counts group_id="E3" events="90" subjects_affected="81" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="407"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="293"/>
                <counts group_id="E3" events="27" subjects_affected="22" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="407"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="33" subjects_at_risk="407"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="293"/>
                <counts group_id="E3" events="33" subjects_affected="29" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

